LambdaVision Announces First Closing of Seed Round to Support Artificial Retina Preclinical Studies - Next Digital Health

LambdaVision, a Connecticut-based biotech company developing a protein-based artificial retina to help restore lost vision due to retinal degeneration diseases, has secured the first close of its seed round. According to the company’s announcement on Wednesday, May 29, 2024, the funding round was led by Aurelia Foundry Fund— a spin-out of MIT. The round also LambdaVision will use the additional funds to scale its manufacturing, support IND-enabling efficacy and toxicity studies, and advance artificial retina pre-clinical studies for retinal diseases.
read more..